News & Events
KaloBios Collaborates to Engineer Human Antibody Therapeutic Drugs
31 / 05 / 2006
Successful completion of first HumaneeringT program and commencement of a broader agreement KaloBios Pharmaceuticals Inc., a privately held biopharmaceutical company, today announced the successful completion of a project for the Genomics Institute of the Novartis…
ASX / Media Announcement - Peptech acquires Promics and accelerates building product pipeline
18 / 05 / 2006
Human Trials Planned for New Australian Lice Control Treatment
15 / 05 / 2006
Potential for shorter treatment times, one-off treatment with lower toxicity Melbourne based biotechnology company Hatchtech Pty Ltd will commence clinical development of a novel head lice control product. The company has appointed a European Contract Research…
Nature Reviews Publication: `MIF: a newcytokine link between rheumatoid arthritis andatherosclerosis'
02 / 05 / 2006
This week, the prestigious journal Nature Reviews Drug Discovery advancepublished online a paper by Assoc Prof Eric Morand, Chief Scientific Officer of Cortical Pty Ltd, and an Associate Professor at the Centre for Inflammatory Diseases, Monash Institute for Medical Research entitled MIF: a…
Pharmaxis Enrols First Patient In Phase III Bronchiectasis Trial
19 / 04 / 2006
Specialist pharmaceutical company Pharmaxis Ltd (ASX:PXS, NASDAQ:PXSL) is pleased to announce that the first of 350 patients has enrolled in its Phase III Bronchitol trial to treat the chronic obstructive lung disease, bronchiectasis; an incurable, degenerative and chronic…
St Vincent's Hospital commences screening patients for C-Pulse TM Trial
13 / 04 / 2006
Key points: - Sunshine Heart, Inc. receives ethics approval to commence its C-PulseT clinical trial program at St Vincent's Hospital in Sydney, NSW - Sunshine Heart, Inc. clinical trial program involves up to 10 patients at centres in Melbourne, Sydney and…
Pharmaxis Completes Enrolment In Aridol Copd Trial
11 / 04 / 2006
Specialist pharmaceutical company Pharmaxis Ltd (ASX:PXS, NASDAQ:PXSL) announced today that it has completed enrolment in its clinical trial to test Aridol's ability to predict response to treatment in patients with Chronic Obstructive Pulmonary Disease (COPD). The trial…
Pharmaxis Secures Licence for Dry Powder Manufacture
06 / 04 / 2006
Specialist pharmaceutical company Pharmaxis Ltd (ASX:PXS, NASDAQ:PXSL) announced today that the Therapeutic Goods Administration (TGA) has reissued its Good Manufacturing Practices (GMP) Licence. The Pharmaxis manufacturing facility in Sydney, Australia was first licensed by…
FDA Approval for Portland Orthopaedics' Knee Replacement
Portland to sell primary knee and soon release revision knee products
06 / 04 / 2006
Portland Orthopaedics Limited (ASX:PLD) knee supplier has been granted US FDA (Food and Drug Administration) approval to sell its Beacon Primary Knee System in the US. As most hip replacement surgeons also replace knees this places Portland in a much stronger market position as a supplier…
Aridol Recommended for Market Authorisation by Adec
13 / 02 / 2006
Specialist pharmaceutical company Pharmaxis Ltd (ASX:PXS, NASDAQ:PXSL) announced today that the Australian Drug Evaluation Committee (ADEC) has recommended to the Therapeutic Goods Administration (TGA) that its first product, AridolT, be registered for sale in Australia. Alan…
MEDCO FORUM - The Renessa System: A New, Non-Surgical Solution for Female Stress Urinary Incontinence
10 / 02 / 2006
Pharmaxis Signs Swiss Marketing Partner for Aridol
06 / 02 / 2006
Specialist pharmaceutical company Pharmaxis Ltd (ASX:PXS, NASDAQ:PXSL) announced today that a new distribution contract for its product, AridolT, has been signed. The agreement, with Trimedal AG, covers the distribution and marketing of Aridol, an asthma management…
Portland Orthopaedics to Register Hip Products and Begin Distributor Searches in China
02 / 02 / 2006
Proacta Inc Announces Phase I Clinical Trial of Novel Prodrug to Target Hypoxic Tumors
24 / 01 / 2006
Alta Partners Tops Off Series A Funding San Diego, CA, January 24, 2005 - Proacta Inc, an early stage biotechnology company, announced today that cancer patient treatment is underway in its Phase I study of PR-104, a hypoxia targeted small molecule…
ASX Gets Hip To Portland Float
21 / 12 / 2005
Helen Schuller, Australian Biotechnology News Hip replacement specialist Portland Orthopaedics (ASX:PLD) has listed on the ASX today at AUD$0.28, three cents above its issue price of $0.25. "We are very excited," said Portland managing director David Sekel. "The…
OPAL Therapeutics Inc, Immunotherapy Start Up, Raises $US6m Series A to target HIV and Hepatitis C.
19 / 12 / 2005
Opal Therapeutics Inc., an immunotherapy development company targeting HIV and Hepatitis C, raises $6 million Series A financing. The company raised the funds from an international syndicate led by GBS Venture Partners, Melbourne, Australia. Other members of…